ADOPT: Improving Diagnosis of Pulmonary Hypertension With AI and Echo

Sponsor
Royal United Hospitals Bath NHS Foundation Trust (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06145880
Collaborator
Janssen Research & Development, LLC (Industry), Royal Free Hospital NHS Foundation Trust (Other), Sheffield Teaching Hospitals NHS Foundation Trust (Other), Royal Papworth Hospital NHS Foundation Trust (Other), NHS Golden Jubilee National Hospital Glasgow (Other)
2,500
1
24
104.1

Study Details

Study Description

Brief Summary

Pulmonary Hypertension (PH) is a condition caused by high blood pressure in the blood vessels that carry blood to the lungs. It can cause severe breathlessness and failure of the right side of the heart. Sadly it is often fatal, and life expectancy ranges from months to years. For some subtypes of PH, effective treatments exist which can improve life expectancy and quality-of-life. Accurate tools for the assessment of PH are therefore essential so that life-saving medications can be started earlier.

In existing diagnostic pathways, evidence for the suspicion of PH is frequently overlooked, significantly delaying the time to diagnosis. Echocardiography (echo) is a quick, safe and well-tolerated test requested to investigate breathless patients, and which can provide useful information about the suspicion of PH. However, outside of specialist PH centres, doctors may not routinely look for and comment on the presence of clues to possible PH.

The investigators think that using Artificial Intelligence (AI) techniques to read echo's could make their interpretation faster and more reliable. There may also be subtle clues to the presence or severity of PH on echo, less recognisable to the human eye, which AI can identify.

In this study the investigators will gather echo images from 5 specialist PH hospitals across the UK which have all been anonymised (patient's name and personal details removed). These will all be historic scans (i.e. have already taken place) and will be grouped into those with PH present (including PH sub-type) or absent. These anonymised echo images will be used to develop and train an AI tool to identify scans where PH is present, including which specific type of PH may be present. The developed AI tool will then be tested on a separate group of scans (not used in the training stage) to validate its performance.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Artificial intelligence tool for transthoracic echocardiography

Detailed Description

In this study the investigators will gather retrospective echo images from 5 specialist PH hospitals across the UK (Royal Free Hospital NHS FT; Sheffield Teaching Hospitals NHS FT; Royal Papworth Hospital NHS FT; NHS Golden Jubilee National Hospital Glasgow; Royal United Hospitals Bath NHS FT).

These will all be historic scans (i.e. have already taken place) and will be grouped into those with PH present (including PH sub-type) or PH absent. Inclusion criteria involve patients aged ≥18 who have undergone both a transthoracic echo (TTE) and a right heart catheter (RHC) as part of their clinical care. Exclusion Criteria will involve patients aged <18, known or suspected congenital heart disease and patients who have opted out of allowing their information to be used for research and planning (via the national data opt-out choice). A clinical case report form (CRF) will be used to capture patient demographics, clinical data with regards to the PH assessment including previous TTE results. Where available, mortality data will be recorded within 5 years of the RHC.

These anonymised echo images will be collated and labelled centrally in a core lab at the RUH Bath, who will work with Janssen to develop and train an AI tool to identify scans where PH is present, including which specific type of PH may be present.

AI tool training will be based on 5 groups (each group anticipated to contain 415 echocardiograms): mild pre-capillary PH; moderate pre-capillary PH; severe pre-capillary PH; post capillary PH; no PH. The tool will then be validated in a separate pool made up of 425 echocardiograms (a combination of pre-capillary, post capillary PH and no PH). The validation cohort will not have been used in the training stage.

Study Design

Study Type:
Observational
Anticipated Enrollment :
2500 participants
Observational Model:
Cohort
Time Perspective:
Retrospective
Official Title:
Artificial Intelligence: Improving Early Detection of Pulmonary Hypertension by Transthoracic Echocardiography: ADOPT
Anticipated Study Start Date :
Dec 1, 2023
Anticipated Primary Completion Date :
Dec 1, 2025
Anticipated Study Completion Date :
Dec 1, 2025

Arms and Interventions

Arm Intervention/Treatment
Mild pre-capillary PH

Right heart catheterisation (performed as part of usual care) diagnoses pulmonary hypertension and categorises it as mild and pre-capillary.

Diagnostic Test: Artificial intelligence tool for transthoracic echocardiography
Pre-defined cohorts will be used to train the artificial intelligence tool for transthoracic echocardiography to improve the diagnosis of PH on TTE.

Moderate pre-capillary PH

Right heart catheterisation (performed as part of usual care) diagnoses pulmonary hypertension and categorises it as moderate and pre-capillary.

Diagnostic Test: Artificial intelligence tool for transthoracic echocardiography
Pre-defined cohorts will be used to train the artificial intelligence tool for transthoracic echocardiography to improve the diagnosis of PH on TTE.

Severe pre-capillary PH

Right heart catheterisation (performed as part of usual care) diagnoses pulmonary hypertension and categorises it as severe and pre-capillary.

Diagnostic Test: Artificial intelligence tool for transthoracic echocardiography
Pre-defined cohorts will be used to train the artificial intelligence tool for transthoracic echocardiography to improve the diagnosis of PH on TTE.

Post capillary PH

Right heart catheterisation (performed as part of usual care) diagnoses pulmonary hypertension and categorises it as post-capillary.

Diagnostic Test: Artificial intelligence tool for transthoracic echocardiography
Pre-defined cohorts will be used to train the artificial intelligence tool for transthoracic echocardiography to improve the diagnosis of PH on TTE.

No PH

Right heart catheterisation (performed as part of usual care) demonstrates normal pulmonary pressures (i.e. no evidence of pulmonary hypertension).

Diagnostic Test: Artificial intelligence tool for transthoracic echocardiography
Pre-defined cohorts will be used to train the artificial intelligence tool for transthoracic echocardiography to improve the diagnosis of PH on TTE.

Outcome Measures

Primary Outcome Measures

  1. Detect patients with pulmonary hypertension (PH) with the novel artificial intelligence tool (AIT) [Month 24]

    Measure the proportion of patients the developed AIT correctly identifies as having PH.

  2. Detect patients without pulmonary hypertension (PH) with the novel artificial intelligence tool (AIT) [Month 24]

    Measure the proportion of patients the developed AIT correctly identifies as not having PH.

  3. Detect patients with pre-capillary pulmonary hypertension (PH) with the novel artificial intelligence tool (AIT) [Month 24]

    Measure the proportion of patients the developed AIT correctly identifies as having pre-capillary PH.

  4. Detect patients with post-capillary pulmonary hypertension (PH) with the novel artificial intelligence tool (AIT) [Month 24]

    Measure the proportion of patients the developed AIT correctly identifies as having post-capillary PH.

  5. Compare the artificial intelligence tool (AIT) performance for detecting pulmonary hypertension (PH) with the current probability criteria [Month 24]

    Compare the proportion of patients identified by the AI tool as having PH with the current guideline criteria for diagnosing PH from a TTE.

  6. Evaluate early detection capabilities of the artificial intelligence tool (AIT) compared to standard of care clinical diagnosis [Month 24]

    Compare the proportion of patients identified by the AI tool as having PH with current standard clinical practice

Secondary Outcome Measures

  1. The novel artificial intelligence tool (AIT) is able to assess the severity of pulmonary hypertension (PH) [Month 24]

    Measure the proportion of patients tested where the AIT accurately diagnoses PH severity

  2. The artificial intelligence tool (AIT) is able to predict mortality [Month 24]

    Measure the proportion of patients where the AIT correctly predicted risk of PH-related mortality

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients aged ≥18

  • Have undergone a transthoracic echo and right heart catheter as part of their routine clinical care.

Exclusion Criteria:
  • Patients aged <18

  • Known or suspected congenital heart disease

  • Patient opted out of allowing their information to be used for research and planning (via the national data opt-out choice).

Contacts and Locations

Locations

Site City State Country Postal Code
1 Royal United Hospitals Bath NHS Foundation Trust Bath United Kingdom BA1 3NG

Sponsors and Collaborators

  • Royal United Hospitals Bath NHS Foundation Trust
  • Janssen Research & Development, LLC
  • Royal Free Hospital NHS Foundation Trust
  • Sheffield Teaching Hospitals NHS Foundation Trust
  • Royal Papworth Hospital NHS Foundation Trust
  • NHS Golden Jubilee National Hospital Glasgow

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Royal United Hospitals Bath NHS Foundation Trust
ClinicalTrials.gov Identifier:
NCT06145880
Other Study ID Numbers:
  • RUH Bath - ADOPT
First Posted:
Nov 24, 2023
Last Update Posted:
Nov 24, 2023
Last Verified:
Aug 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Royal United Hospitals Bath NHS Foundation Trust
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 24, 2023